Stockscreener 앱 받기
16.94
0.18%
0.03
시간 외 거래:
16.85
-0.09
-0.53%
전일 마감가:
$16.91
열려 있는:
$16.97
하루 거래량:
1.84M
Relative Volume:
1.18
시가총액:
$1.50B
수익:
$203.45M
순이익/손실:
$-351.45M
주가수익비율:
-3.7231
EPS:
-4.55
순현금흐름:
$-369.41M
1주 성능:
+8.38%
1개월 성능:
+10.72%
6개월 성능:
-22.11%
1년 성능:
+98.59%
1일 변동 폭
$16.55
$17.34
1주일 범위
$15.42
$17.45
52주 변동 폭
$8.31
$25.29
Travere Therapeutics Inc Stock (TVTX) Company Profile
명칭
Travere Therapeutics Inc
전화
888-969-7879
주소
3611 VALLEY CENTRE DR, SAN DIEGO
TVTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
16.94 | 1.53B | 203.45M | -351.45M | -369.41M | -4.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-11 | 재확인 | Citigroup | Buy |
| 2025-06-11 | 재개 | H.C. Wainwright | Buy |
| 2025-01-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-10-21 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-09-09 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2024-03-27 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-12-05 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-11-20 | 개시 | Citigroup | Neutral |
| 2023-09-22 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-09-21 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-09-06 | 재개 | Evercore ISI | Outperform |
| 2023-07-21 | 개시 | JP Morgan | Overweight |
| 2023-06-07 | 재개 | Piper Sandler | Neutral |
| 2023-05-22 | 개시 | TD Cowen | Outperform |
| 2023-05-05 | 업그레이드 | Bryan Garnier | Sell → Neutral |
| 2023-03-01 | 개시 | Guggenheim | Buy |
| 2023-02-21 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2022-12-14 | 개시 | Stifel | Hold |
| 2022-12-05 | 개시 | Wells Fargo | Overweight |
| 2022-09-21 | 개시 | Bryan Garnier | Sell |
| 2022-07-14 | 재개 | Canaccord Genuity | Buy |
| 2022-03-31 | 개시 | Piper Sandler | Overweight |
| 2022-02-28 | 개시 | H.C. Wainwright | Buy |
| 2021-05-26 | 다운그레이드 | Wedbush | Outperform → Neutral |
모두보기
Travere Therapeutics Inc 주식(TVTX)의 최신 뉴스
Travere Therapeutics price target raised to $34 from $32 at Citi - TipRanks
Travere Therapeutics, Inc. (NASDAQ:TVTX) Q2 2025 Earnings Call Transcript - MSN
Travere Therapeutics Reports Strong Q2 2025 Growth - MSN
Travere Therapeutics price target raised to $32 from $30 at Wedbush - Yahoo Finance
Travere Therapeutics Earnings Call Highlights FILSPARI Success - TipRanks
Scotiabank Raises Price Target for Travere Therapeutics (TVTX) t - GuruFocus
Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Path To Profitability - simplywall.st
Travere Therapeutics price target raised to $31 from $30 at Scotiabank - TipRanks
Stifel lowers Travere Therapeutics stock price target to $20 on FSGS approval uncertainty - Investing.com
Stifel lowers Travere Therapeutics stock price target to $20 on FSGS approval uncertainty By Investing.com - Investing.com South Africa
Wedbush Lifts Price Target on Travere Therapeutics to $32 From $30, Keeps Outperform Rating - MarketScreener
TVTX: Wedbush Raises Price Target and Maintains Outperform Ratin - GuruFocus
Travere: Q2 Earnings Snapshot - Huron Daily Tribune
Travere signals accelerating FILSPARI growth and prepares for FSGS launch while advancing REMS modifications - MSN
Earnings call transcript: Travere Therapeutics Q2 2025 beats revenue forecasts - Investing.com Canada
Travere Therapeutics Reports Second Quarter 2025 Financial Results - BioSpace
Travere Therapeutics: Scaling the Rare Disease Ladder—Can FILSPARI Sustain Its Momentum? - AInvest
Contradictions Unveiled: Travere Therapeutics' 2025Q2 Earnings Call Highlights Regulatory Challenges and Market Dynamics - AInvest
Transcript : Travere Therapeutics, Inc., Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Travere Therapeutics 2025 Q2 Earnings Strong Performance with 81.9% Net Loss Reduction - AInvest
Here's What Key Metrics Tell Us About Travere (TVTX) Q2 Earnings - Yahoo Finance
Travere Therapeutics, Inc. SEC 10-Q Report - TradingView
Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Travere Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Travere Therapeutics shares rise as Q2 results top expectations By Investing.com - Investing.com Australia
Travere Therapeutics shares rise as Q2 results top expectations - Investing.com India
Travere Therapeutics Inc Reports Q2 2025 Earnings: EPS Loss of $0.14 Beats Estimates, Revenue Surpasses Expectations at $114.4 Million - GuruFocus
Travere Therapeutics earnings beat by $0.16, revenue topped estimates - Investing.com Canada
Is Travere Therapeutics (NASDAQ:TVTX) Using Too Much Debt? - 富途牛牛
Travere Therapeutics to Participate at Upcoming Investor ConferencesAugust 5, 2025 - BioSpace
Earnings Preview: Travere Therapeutics - 富途牛牛
Trend Dashboard Flags Travere Therapeutics Inc. As Potential Swing TradeExpert Verified Stock Trade Ideas Backed by Data - metal.it
What are the technical indicators suggesting about Travere Therapeutics Inc.Achieve triple-digit returns with smart investing - Jammu Links News
Should I hold or sell Travere Therapeutics Inc. stock in 2025Grow your portfolio with growth-oriented stocks - Jammu Links News
How does Travere Therapeutics Inc. generate profit in a changing economyFree Investment Community - Jammu Links News
When is Travere Therapeutics Inc. stock expected to show significant growthDouble or triple returns - Jammu Links News
How many analysts rate Travere Therapeutics Inc. as a “Buy”Explosive capital gains - Jammu Links News
Is Travere Therapeutics Inc. a good long term investmentUnlock market-leading stock analysis - Jammu Links News
How does Travere Therapeutics Inc. compare to its industry peersExceptional trading performance - Jammu Links News
How strong is Travere Therapeutics Inc. company’s balance sheetPost Market Guidance With High Returns - jammulinksnews.com
What is Travere Therapeutics Inc. company’s growth strategyTop Growth Data Feed From AI Tools - jammulinksnews.com
Travere Therapeutics to Report Second Quarter 2025 Financial Results - BioSpace
Why Travere Therapeutics Inc. stock attracts strong analyst attentionAccurate Buy Point for Momentum Stocks Detected - beatles.ru
Travere Therapeutics Inc. Matches Institutional Buying FilterDaily Momentum Screener With Alerts Launched - metal.it
Why is Travere Therapeutics Inc. stock attracting strong analyst attentionStock Market Guidance With High Returns - Jammu Links News
What are analysts’ price targets for Travere Therapeutics Inc. in the next 12 monthsReal Time Watchlist To Watch Now - jammulinksnews.com
What are Travere Therapeutics Inc. company’s key revenue driversGet timely alerts on market opportunities - Jammu Links News
Travere Therapeutics Inc (TVTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):